Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Trastuzumab (Herceptin) and Capecitabine (Xeloda) in Women With Taxanes and Anthracyclines Refractory Metastatic Breast Cancer and HER2 Over-Expression

NCT00107393 is registered in ClinicalTrials.gov with Tohoku University as lead sponsor.

NCT NCT00107393
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00107393 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Trastuzumab (Herceptin) and Capecitabine (Xeloda) in Women With Taxanes and Anthracyclines Refractory Metastatic Breast Cancer and HER2 Over-Expression
Lead sponsor
Tohoku University
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2003
Completion date
November 30, 2008
Enrollment
75 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer